Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics presented initial clinical data for FT522, its off-the-shelf, ADR-armed CAR NK cell product for B-cell lymphoma and autoimmune diseases. In the Phase 1 lymphoma study, FT522 showed a favorable safety profile with complete responses and demonstrated ability to persist and target CD19+ B cells without conditioning chemotherapy. The company is initiating a Phase 1 basket study for B cell-mediated autoimmune diseases as an add-on to standard treatments. Initial data showed no dose-limiting toxicities, with complete responses observed in indolent lymphoma patients and partial responses in other lymphoma types. The study revealed dose-dependent activity and successful B-cell depletion, supporting FT522's potential in treating autoimmune conditions.

Fate Therapeutics reported Q3 2024 financial results and clinical updates. Key highlights include initial clinical data from three Phase 1 studies: FT819 in autoimmunity, FT522 in B-cell lymphoma, and FT825/ONO-8250 in solid tumors. The company reported $330.5 million in cash and investments, with Q3 revenue of $3.1 million and operating expenses of $55.5 million. FT819's Phase 1 study in lupus patients showed no significant safety concerns, and a new treatment arm without conditioning chemotherapy was opened. FT522 received FDA approval for a multi-indication IND in autoimmune diseases, while FT825 demonstrated favorable safety profiles in initial low-dose cohorts.

Fate Therapeutics (NASDAQ: FATE) presented initial clinical and preclinical data for FT825/ONO-8250, a CAR T-cell therapy targeting HER2 in advanced solid tumors. The Phase 1 study's first low-dose cohort of three heavily pre-treated patients showed favorable safety outcomes with no dose-limiting toxicities or adverse events. The therapy demonstrated CAR T-cell expansion and maintained activation state at Day 8 post-treatment.

The product incorporates a novel H2CasMab-2 binding domain designed to overcome on-target, off-tumor toxicity. Preclinical data showed selective targeting of cancer cells while limiting effects on normal HER2+ cells. The study continues enrollment at higher doses and in combination with EGFR-targeted antibody therapy.

Fate Therapeutics presented preclinical data for FT836, a novel CAR T-cell product candidate targeting MICA/B proteins expressed on cancer cells, at the 2024 SITC Annual Meeting. FT836 incorporates the company's Sword & Shield technology, designed to promote functional persistence without conditioning chemotherapy. The preclinical data demonstrated robust antigen-mediated expansion and durable anti-tumor activity across various solid tumors. The product uniquely targets the α3 domain of MICA/B, stabilizing expression and inducing cytolytic killing of tumor cells. Notably, treatment with chemotherapy or radiation therapy enhanced FT836's cytolytic activity, suggesting potential combination therapy opportunities.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted 20,000 restricted stock units (RSUs) to a new non-executive employee. The RSUs were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. On October 1, 2024, the company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees.

The grants were approved by the Compensation Committee of Fate Therapeutics' Board of Directors under the company's Amended and Restated Inducement Equity Plan. These RSUs will vest over four years, with 25% of the shares vesting on each anniversary of the grant date, contingent on continuous employment. The awards comply with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining the company.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, will present on Thursday, September 19, 2024, at 12:45 PM ET in New York.

Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Fate Therapeutics' website. The archived version will be available shortly after the event concludes. This conference appearance provides an opportunity for Fate Therapeutics to showcase its innovative pipeline and progress in the field of cellular immunotherapies to a global audience of healthcare professionals and investors.

Fate Therapeutics (NASDAQ: FATE) reported Q2 2024 financial results and business updates. Key highlights include:

1. Ongoing enrollment in FT819 Phase 1 autoimmunity study for SLE, now including single-agent cyclophosphamide as an alternative conditioning regimen.

2. First patient treated with FT522 CAR NK cell product in conditioning-free arm of Phase 1 B-cell lymphoma study.

3. FT522 multi-indication IND for autoimmune diseases to be submitted in Q3 2024.

4. Enrollment ongoing for FT825/ONO-8250 CAR T-cell product in Phase 1 solid tumor study.

5. $352 million in cash and investments, with projected runway through 2026.

6. Q2 2024 revenue of $6.8 million, including a $5 million milestone from Ono Pharmaceutical.

7. GAAP operating expenses of $51.9 million for Q2 2024.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. On August 1, 2024, the company granted restricted stock units (RSUs) representing 34,200 shares of common stock to four newly-hired non-executive employees. These grants were approved by the Compensation Committee and issued under the company's Amended and Restated Inducement Equity Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.